Clinical trials
Advanced Solid Tumor clinical trials
Below are recruiting advanced solid tumor clinical trials, each written for real people, not researchers. We’re tracking 1,391 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07281326RecruitingPhase 1
A study of AK138D1 for advanced solid tumors
This trial tests a new drug called AK138D1 for people with advanced solid tumors. It aims to see if the drug is safe and how well it works, especially for tumors that haven't been treated with HER3-targeted therapy before.
Harbin, HeilongjiangAges 18–75 - NCT06509490Recruiting
CAR-T cell therapy for advanced NKG2DL-positive solid tumors
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18–70 - NCT06380309RecruitingEarly Phase 1
Study of experimental drug IDOV-SAFE for advanced digestive cancers
This trial tests an investigational drug for people with advanced digestive system cancers (like colorectal, stomach, or liver cancer) that have stopped responding to standard treatments. The goal is to see if the drug is safe and helps control the cancer.
BeijingAges 18–75 - NCT04969315RecruitingPhase 1/Phase 2
Drug TT-10 and TT-4 for advanced solid tumors
This early-phase trial tests two investigational drugs—TT-10 and TT-4—alone and together in people with advanced solid cancers. The study is designed to find safe doses and see if the treatment can shrink tumors or slow cancer growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05159245RecruitingPhase 2
Targeted drug access for adults with advanced cancer
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
Turku, Southwest FinlandAges 18–100 - NCT05947695Recruiting
Nurse-led comfort and survivorship care for advanced cancer
This study looks at whether a specialized nurse-led care plan soon after diagnosis/treatment helps people living with advanced (metastatic) cancer. It focuses on patients expected to do better than average based on certain prognosis factors.
West Islip, New YorkAges 21 years+ - NCT06014658RecruitingPhase 1/Phase 2
Study of MBRC-101 for advanced solid tumors
This trial tests a new drug, MBRC-101, that targets a protein called EphA5 found on some cancer cells. It is for people with advanced solid tumors (like lung, breast, or pancreatic cancer) that have stopped responding to other treatments. The study aims to find a safe dose and see if the drug can shrink tumors.
San Francisco, CaliforniaAges 18 years+ - NCT06043466RecruitingPhase 1
CAR-T cell therapy for CEA-positive advanced solid tumors
This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06126406RecruitingPhase 1
CEA-targeting CAR-T cell therapy for advanced solid tumors
This trial tests a new immune cell therapy (CAR-T) designed to attack cancer cells that make a protein called CEA. It may be an option for people with advanced colorectal, esophageal, gastric, or pancreatic cancer who have already tried at least two standard treatments.
Wuhu, AnhuiAges 18 years+ - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
Sarasota, FloridaAges 18 years+ - NCT06821048RecruitingPhase 1
CAR-T cells targeting CEA for advanced solid tumors
This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.
Hangzhou, ZhejiangAges 18 years+ - NCT06914674RecruitingPhase 2
Tamoxifen for advanced pancreatic SPTP
This trial tests whether tamoxifen, a hormone therapy drug, can shrink or slow down advanced solid pseudopapillary tumors of the pancreas (SPTP) that have estrogen and progesterone receptors. It may be an option for people whose tumors cannot be removed by surgery or have come back after other treatments.
ShanghaiAges 14–80 - NCT06937567RecruitingEarly Phase 1
CDH17 car-t therapy for advanced solid tumors
This trial tests a new treatment called CDH17 CAR-T for people with advanced solid tumors like colorectal, stomach, pancreatic, or bile duct cancer. It is for patients who have tried other treatments without success. The therapy uses your own immune cells, modified to target a protein called CDH17 found on some cancer cells.
Hangzhou, ZhejiangAges 18–70 - NCT07121036RecruitingPhase 1
High-dose vitamin C infusion for advanced solid tumors
This trial tests a special high-dose vitamin C infusion, given based on how your body processes it, for people with advanced solid tumors. It aims to see if this vitamin C therapy can be safely combined with your current or new chemotherapy to help control the cancer.
Wuhan, HubeiAges 18–75 - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07229768RecruitingEarly Phase 1
Study of 177Lu-CTR-FAPI for advanced solid tumors
This trial tests a radioactive drug called 177Lu-CTR-FAPI for people with advanced solid tumors that have not responded to standard treatments. It targets tumors that show a specific protein (FAP) on PET scans. The study focuses on certain cancers like pancreatic, breast, and soft tissue sarcoma.
ShanghaiAges 18–85 - NCT07426094RecruitingPhase 2/Phase 3
Boosting radiation for prostate cancer in lymph nodes
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06908434RecruitingPhase 1
GenSci128 for solid tumors with TP53 Y220C mutation
This trial tests a new drug, GenSci128, for people whose solid tumors have a specific TP53 Y220C mutation. The drug aims to reactivate the p53 protein to fight cancer. It is for patients who have exhausted standard treatments.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07111546RecruitingPhase 2
A study of LBL-024 combination for advanced solid tumors
This trial tests a new drug combination (LBL-024) for people with advanced solid tumors, including bile duct and liver cancers. It aims to see if the treatment is safe and effective for those who have not responded to other therapies.
Nanning, GuangxiAges 18–75 - NCT06612840RecruitingPhase 1
A study of GNC-077 for advanced lung cancer and other solid tumors
This trial tests a new drug called GNC-077 for people with advanced non-small cell lung cancer or other solid tumors that have spread. It aims to see if the drug is safe and helps shrink tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07056556RecruitingPhase 1
Study of BL-M09D1 for advanced lung and other solid tumors
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07232524RecruitingPhase 1
BL-M24D1 for advanced head and neck and other solid tumors
This study tests a new drug called BL-M24D1 in people with head and neck cancer or other solid tumors that have spread or cannot be surgically removed. The goal is to see if the drug is safe and can help shrink tumors.
Chengdu, SichuanAges 18 years+ - NCT06805825RecruitingPhase 1
Study of NN3201 for advanced cancers with c-Kit
This trial tests a new drug, NN3201, that targets a protein called c-Kit found on some cancer cells. It may be an option for people with certain advanced solid tumors, including GIST, small cell lung cancer, or other c-Kit-positive cancers, who have already tried standard treatments or cannot take them.
Ann Arbor, MichiganAges 18 years+ - NCT06031584RecruitingPhase 1/Phase 2
Testing BL-M07D1 for HER2-positive or low solid tumors
This trial tests a new drug called BL-M07D1 for people with certain advanced solid tumors that have the HER2 protein (high or low amounts). The goal is to see if it can shrink or slow the growth of these cancers, especially in urinary and digestive system tumors.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor?
- Yes. Clin2 currently lists 1,391 recruiting advanced solid tumor studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.